Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.82 |
| ▸ | AKT2 | P31751 | 10/20 | 0.80 |
| ▸ | AKT3 | Q9Y243 | 7/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188135 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3 | |
| SCHEMBL2175021 | 0.89 | AKT1 (1.00) | AKT1AKT2AKT3 | |
| SCHEMBL12853962 | 0.88 | AKT1 (0.63) | AKT1AKT2AKT3 | |
| SCHEMBL12854011 | 0.88 | AKT1 (0.63) | AKT1AKT2AKT3 | |
| SCHEMBL13570613 | 0.88 | AKT1 (0.76) | AKT1AKT2AKT3 | |
| SCHEMBL2190840 | 0.88 | AKT1 (0.81) | AKT1AKT2AKT3 | |
| SCHEMBL2188534 | 0.88 | AKT1 (0.81) | AKT1AKT2AKT3 | |
| SCHEMBL2193872 | 0.86 | AKT1 (1.00) | AKT1AKT2AKT3 | |
| SCHEMBL30815163 | 0.85 | AKT1 (0.82) | AKT1AKT2AKT3 | |
| SCHEMBL2191672 | 0.85 | AKT1 (1.00) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3189036-B1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ARQULE INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-103748093-A | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE INC | 2014-04-23 | — | — | CN | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-8609688-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2012177844-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2519522-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | AKT1 3351/4885AKT2 4101/4885AKT3 4413/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | AKT1 3842/4885AKT2 4044/4885AKT3 3228/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | AKT1 1422/4885AKT2 1217/4885AKT3 1479/4885 |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885AKT3 1380/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | AKT1 3384/4885AKT2 3638/4885AKT3 3718/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | AKT1 37/4885AKT2 47/4885AKT3 66/4885 |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885AKT3 1380/4885 |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885AKT3 1380/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | AKT1 3279/4885AKT2 3746/4885AKT3 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.